CAS: 25451-15-4; 2-Phenylpropane-1,3-Diyl Dicarbamate

该化合物是一种主要用于治疗癫痫的抗抽搐药物,特别是针对未对其他治疗作出充分反应的病人.它被归类为氨酸甲酯衍生物,具有独特的行动机制,涉及对NMDA受体进行调制和增强GABA活性,这有助于稳定...

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

上下游产品

CAS号1570-95-2 2-苯基-1,3-丙二醇 | CAS号917-61-3 氰酸钠 | CAS号25451-53-0 3-羟基-2-氨基甲酸苯丙酯 | CAS号530-62-1 N,N'-羰基二咪唑(CDI) | CAS号1189-71-5 氯磺酰异氰酸酯 | CAS号83-13-6 苯基丙二酸二乙酯 | CAS号51-79-6 氨基甲酸乙酯

合成工艺路线路线简述

    2-Fluoro-2-Phenyl-1,3-Propanediol 以82%的收率获得非氨酯
    参考文献:Felbamate Derived Compounds
    标题:Felbamate Derived Compounds
    摘要:本发明涉及新型费巴酯衍生物及其用于治疗癫痫等神经系统疾病和治疗因缺血事件导致的组织损伤的用途.费巴酯衍生物经过改良,以防止形成被认为与费巴酯疗法相关的毒性代谢物.

    海关参考信息

    专利信息


    专利号:WO-2021233976-A1
    优先权日:2020-05-19
    标 题 :Process for the synthesis of isocyanate-free omega-hydroxy-urethanes, alpha-omega-diurethanes and oligo (poly)urethanes
    发明人:NOCITO FRANCESCO; ARESTA MICHELE; DIBENEDETTO ANGELA
    权利人:CONSORZIO INTERUNIVERSITARIO NAZ PER LA REATTIVITA CHIMICA E LA CATALISI; CATALISI INNOVATIVA PER IL RICICLO DEL CARBONIO E BIOPOLIMERI S R L
    摘要:The synthesis of omega-hydroxyalkyl-urethanes, and of alfa-omega-diurethanes is reported which includes the reaction of diols with urea in presence of catalysts based on Ce at temperatures between 125 and 170°C over 4-8 h reaction time. A process for the production of oligomers of omega-hydroxyalkyl-urethanes is also reported based on the reaction of urea with diols in presence of Ce or Zr catalysts or Ce mixed oxides at 125-170°C over 4-20 h.

    专利号:US-6630602-B1
    优先权日:1998-04-16
    标题 :Propylisopropyl acetic acid and propylisopropyl acetamide stereoisomers, a method for their synthesis and pharmaceutical compositions containing them
    发明人:BIALER MEIR; SPIGELSTEIN OFER; YAGEN BORIS
    权利人:YISSUM RES DEV CO
    摘要:The present invention relates to racemic propylisopropyl acetic acid and propylisopropyl acetamide and their isomers in their racemic and stereospecific forms, for use in treatment of neurological and psychotic disorders, and affective disorders and to treat pain, headaches and migraines. The isomers are of the compound formula I:wherein R1 is a methyl or ethyl group; R2 is H, methyl or an ethyl group; R3 is ethyl or a propyl group; and R4 is a hydroxyl or amide group; and the total number of carbon atoms in said compound is 8, provided that when R1 is a methyl group and R4 is an amide group, R2 and R3 are not ethyl, further provided that when R1 is an ethyl and R4 a hydroxyl group, only stereoisomers of the compound are referred to. The present invention further relates to a method for the stereoselective synthesis of the 2S and 2R stereoisomer of PID and PIA. The present invention also relates to pharmaceutical compositions containing as an active ingredient a racemic mixture or stereoisomers of the compounds of the general formula (I), which are useful for the treatment of neurological and psychotic disorders, and affective disorders and to treat pain, headaches and migraines.

    专利号:US-6969732-B2
    优先权日:1999-04-12
    标 题 :Propylisopropyl acetic acid and propylisopropyl acetamide stereoisomers, a method for their synthesis and pharmaceutical compositions containing them
    发明人:BIALER MEIR; SPIGELSTEIN OFER; YAGEN BORIS
    权利人:YISSUM RES DEV CO
    摘要:The present invention relates to racemic propylisopropyl acetic acid and propylisopropyl acetamide and their isomers in their racemic and stereospecific forms, for use in treatment of neurological and psychotic disorders, and affective disorders and to treat pain, headaches and migraines. The isomers are of the compound formula I n n R 1 is a methyl or ethyl group; R 2 is H, methyl or an ethyl group; R 3 is ethyl or a propyl group; and R 4 is a hydroxyl or amide group,n nand the total number of carbon atoms in said compound is 8, provided that when R1 is a methyl group and R4 is an amide group, R2 and R3 are not ethyl, further provided that when R1 is an ethyl and R4 a hydroxyl group, only stereoisomers of the compound are referred to.n nn The present invention further relates to a method for the stereoselective synthesis of the 2R stereoisomer of PID and PIA. The present invention also relates to pharmaceutical compositions containing as an active ingredient a racemic mixture or stereoisomers of the compounds of the general formula (I), which are useful for the treatment of neurological and psychotic disorders, and affective disorders and to treat pain, headaches and migraines.

    专利号:US-2006241298-A1
    优先权日:2005-04-21
    标 题:Methods for synthesis of dicarbamate compounds and intermediates in the formation thereof
    发明人:MORTKO HENRY; HE WEIXUAN; ANDERSEN MARC W; DOTSE ANTHONY K; LI JIE
    权利人:MORTKO HENRY; HE WEIXUAN; ANDERSEN MARC W; DOTSE ANTHONY K; LI JIE
    摘要:Disclosed is a method of making 2-substituted-2-halo-1,3-propanediols via reduction of corresponding malonate compounds. Also disclosed is a method of making 2-substituted-2-halo-1,3-dicarbamate compounds (such as halo derivatives of felbamate, including fluorofelbamate) via reduction of malonate compounds, followed by carbamoylation. Reduction of the malonate compounds is carried out using an electrophilic hydride reagent.

    专利号:US-2008214827-A1
    优先权日:2004-02-03
    标 题:Synthesis of Cyanoimino-Benzoimidazoles
    发明人:GOEHRING R RICHARD; WHITEHEAD JOHN; SHAO BIN
    权利人:EURO CELTIQUE SA
    摘要:Disclosed in certain embodiments is a process for synthesizing a compound of formula (V) and salts thereof.

    专利号:US-2011040105-A1
    优先权日:2008-04-16
    标题 :Processes useful for the synthesis of (r)-1--2-methyl-pyrrolidine
    发明人:HUBER CHRISTIAN H; KHULMAN YOUNG MI; TANDEL SAGUN K; JOHANNSEN STEPHEN R; WANG TINGMIN; ANGELL PAUL
    权利人:ARENA PHARM INC
    摘要:Processes useful for making a pharmaceutically useful compound according to Formula (I), forms of such a compound, and intermediates useful in such processes are described.
    浙江黄岩三力化工厂
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    电话:0792-6529888 0576-4273870👤
    ⚠️参考联系方式
    邮件:sales@ztpharm.com
    销售经理: 叶仙春经理
    联系电话:0792-6529888 0576-4273870
    传真号码: 07926529766 05764273744
    江西省九江市湖口金砂湾工业城
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    江西省九江市湖口金砂湾工业城
    ⚠️ 未注册 · 未认证企业
    注册入口 声明: 数据来源:本内容基于各搜索引擎等公开数据整理,仅作展示用。请自行辨别 📄若企业需抹除相关内容或, 请联系方我们,我们即刻栓除。
    台州海辰药业有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    电话:576-85588852👤
    ⚠️参考联系方式
    邮件:sales@highsunpharm.com
    联系电话:86-576-85588852
    传真号码: 86-576-85588152
    (国家级)浙江省化学原料药基地临海沿海工业园区
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    浙江省化学原料药基地临海沿海工业园区
    ⚠️ 未注册 · 未认证企业
    注册入口 声明: 数据来源:本内容基于各搜索引擎等公开数据整理,仅作展示用。请自行辨别 📄若企业需抹除相关内容或, 请联系方我们,我们即刻栓除。
    台州市春泉医化有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    电话:+86-576-84273944👤
    ⚠️参考联系方式
    地址:浙江黄岩城柏树家园8幢803室. 邮编:318020
    电话:+86-576-84273944
    传真:+86-576-84291447
    邮箱:935730889@qq.com
    联系人:叶艺
    手机:13362612008
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    浙江黄岩城柏树家园8幢803室
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    上海孚一生物科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    电话:0551-62888437👤
    ⚠️参考联系方式
    邮件:sales@creditasiachem.com
    销售经理: 戴经理
    联系电话:0551-62888437
    手机号码: 18096642264
    传真号码: 055162888437
    QQ号:3411695379
    上海
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    浦东新区年家浜路528号
    ⚠️ 未注册 · 未认证企业
    注册入口 声明: 数据来源:本内容基于各搜索引擎等公开数据整理,仅作展示用。请自行辨别 📄若企业需抹除相关内容或, 请联系方我们,我们即刻栓除。
    武汉元特科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    电话:27-83229660👤
    ⚠️参考联系方式
    邮件:sales@pharmnetcn.com
    销售经理: 尹女士经理
    联系电话:86-27-83229660
    手机号码: 86-13657289573
    传真号码: 86-27-83082226
    QQ号:1875301637
    东西湖区二支沟海景1路2号
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    东西湖区二支沟海景1路2号
    ⚠️ 未注册 · 未认证企业
    注册入口 声明: 数据来源:本内容基于各搜索引擎等公开数据整理,仅作展示用。请自行辨别 📄若企业需抹除相关内容或, 请联系方我们,我们即刻栓除。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Shi LL, Dong J, Ni H, Geng J, Wu T. Felbamate as an add-on therapy for refractory epilepsy. Cochrane Database Syst Rev. 2014 Jul 18;7:CD008295. doi: 10.1002/14651858.CD008295.pub3. Review. doi: 10.1002/14651858.CD008295.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;7:CD008295. [Therapeutic drug monitoring of felbamate]. Therapie. 2010 Jan-Feb;65(1):35-8. doi: 10.2515/therapie/2009068. Epub 2010 Mar 8. Review. French. Epub 2006 Aug 4. Review. Review. Review. Review. Review. Review. Review. Review. Review. Review. Review. Erratum in: Semin Pediatr Neurol 1998 Mar;5(1):76. Review. Review. Spanish. Review. Review. Spanish. Review. Review. German.

    合成参考文献


    参考文献:10.2165/11530220-000000000-00000
    摘要:Michoulas A, Farrell K. Medical management of Lennox-Gastaut syndrome. CNS Drugs. 2010 May;24(5):363–74. doi: 10.2165/11530220-000000000-00000.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知